Emerging Therapeutic Drugs in Metastatic Triple-Negative Breast Cancer.
Metastatic triple-negative breast cancer (TNBC) is a heterogeneous disease with a poor prognosis and currently with few treatment options. Treatment of these patients is highly based on systemic chemotherapy. Some targeted drugs were recently approved for these patients: two poly(ADP-ribose) polymer...
| Publicado en: | Breast Cancer: Basic & Clinical Research pp. 1 - 15 |
|---|---|
| Autores principales: | , |
| Formato: | review tables/charts Journal Article |
| Publicado: |
Sage Publications Inc.
1/1/2021
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=154320923&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 154320923 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 11782234 B078 jtl: Breast Cancer: Basic & Clinical Research issn: 11782234 maglogo: Y pubinfo: dt: 1/1/2021 pid: 344 pub: Sage Publications Inc. place: Thousand Oaks, California artinfo: ui: 154320923 154320923 154320923 10.1177/11782234211002491 154320923 ppf: 1 ppct: 14 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Emerging Therapeutic Drugs in Metastatic Triple-Negative Breast Cancer. aug: au: Cipriano, Élia Mesquita, Alexandra affil: Medical Oncology Department, Hospital Pedro Hispano, Matosinhos Local Health Unit, Matosinhos, Portugal sug: subj: Breast Neoplasms Drug Therapy Neoplasm Metastasis Drug Therapy Antineoplastic Agents, Combined Therapeutic Use Chemotherapy, Cancer Mutation Gene Expression Programmed Cell Death Ligand 1 Immune Checkpoint Inhibitors Receptors, Androgen Antagonists and Inhibitors Clinical Trials Signal Transduction ab: Metastatic triple-negative breast cancer (TNBC) is a heterogeneous disease with a poor prognosis and currently with few treatment options. Treatment of these patients is highly based on systemic chemotherapy. Some targeted drugs were recently approved for these patients: two poly(ADP-ribose) polymerase inhibitors in patients with germline BRCA1/2 mutations (olaparib and talazoparib), immune checkpoint inhibitors in association with chemotherapy if programmed death-ligand 1 positive (atezolizumab plus nabpaclitaxel and pembrolizumab plus chemotherapy [nabpaclitaxel, paclitaxel, and carboplatin plus gemcitabine]), and an antibody-drug conjugate sacituzumab-govitecan in heavily pretreated patients (at least 2 previous lines for the metastatic setting). Combinations using these and other targeted treatment options are under investigation in early and late clinical trials, and we will probably have some practice-changing results in the new future. Other targeted drugs explored in phase II and phase III clinical trials are PI3K/AKT pathway inhibitors and androgen receptor antagonists in patients with alterations in these signaling pathways. The definition of molecular subtypes has been essential for the development of these treatment strategies. Soon, the treatment of metastatic TNBC could be based on personalized medicine using molecular testing for targeted drugs instead of only systemic chemotherapy. The authors present a review of emerging treatment options in metastatic TNBC, focusing on targeted drugs, including the recent data published in 2020. pubtype: Academic Journal doctype: review tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|